surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 cuts risk by 94% in SURMOUNT-1 trial Subcutaneously administered tirzepatide vs semaglutide

At week 112, mean weight change from baseline was 22.4% with MTD (representing 100% maintenance prior to weight reduction), 17.0% with 5mg (~70% maintenance), and 10.1% with placebo

At Arden Creek Laser and Aesthetics, we are committed to offering the latest advancements in medical weight loss to help our clients achieve their health and wellness goals

Note dose initiation and escalation schedule

Read our guide to weight loss shots and how they work

Abstract Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, represents a new class of incretin-based therapy for type 2 diabetes mellitus (T2DM), obesity, and related comorbidities